Prophylactic Human Vaccine Market Report

Global Prophylactic Human Vaccine Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：182
  • REPORT CODE：GMM861731
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Prophylactic Human Vaccine market report explains the definition, types, applications, major countries, and major players of the Prophylactic Human Vaccine market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Merck

    • GSK

    • Merial

    • Sanofi

    • McKesson Medical

    • Biovac

    • Zoetis

    By Type:

    • Inactivated Vaccine

    • Attenuated Vaccine

    • Others

    By End-User:

    • Hospital

    • Scientific Research

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Prophylactic Human Vaccine Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Prophylactic Human Vaccine Outlook to 2028- Original Forecasts

    • 2.2 Prophylactic Human Vaccine Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Prophylactic Human Vaccine Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Prophylactic Human Vaccine Market- Recent Developments

    • 6.1 Prophylactic Human Vaccine Market News and Developments

    • 6.2 Prophylactic Human Vaccine Market Deals Landscape

    7 Prophylactic Human Vaccine Raw Materials and Cost Structure Analysis

    • 7.1 Prophylactic Human Vaccine Key Raw Materials

    • 7.2 Prophylactic Human Vaccine Price Trend of Key Raw Materials

    • 7.3 Prophylactic Human Vaccine Key Suppliers of Raw Materials

    • 7.4 Prophylactic Human Vaccine Market Concentration Rate of Raw Materials

    • 7.5 Prophylactic Human Vaccine Cost Structure Analysis

      • 7.5.1 Prophylactic Human Vaccine Raw Materials Analysis

      • 7.5.2 Prophylactic Human Vaccine Labor Cost Analysis

      • 7.5.3 Prophylactic Human Vaccine Manufacturing Expenses Analysis

    8 Global Prophylactic Human Vaccine Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Prophylactic Human Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Prophylactic Human Vaccine Export by Region (Top 10 Countries) (2017-2028)

    9 Global Prophylactic Human Vaccine Market Outlook by Types and Applications to 2022

    • 9.1 Global Prophylactic Human Vaccine Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Inactivated Vaccine Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Attenuated Vaccine Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global Prophylactic Human Vaccine Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Scientific Research Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Prophylactic Human Vaccine Market Analysis and Outlook till 2022

    • 10.1 Global Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.2.2 Canada Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.2.3 Mexico Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.2 UK Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.3 Spain Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.4 Belgium Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.5 France Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.6 Italy Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.7 Denmark Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.8 Finland Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.9 Norway Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.10 Sweden Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.11 Poland Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.12 Russia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.3.13 Turkey Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.2 Japan Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.3 India Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.4 South Korea Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.5 Pakistan Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.6 Bangladesh Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.7 Indonesia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.8 Thailand Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.9 Singapore Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.10 Malaysia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.11 Philippines Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.4.12 Vietnam Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.2 Colombia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.3 Chile Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.4 Argentina Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.5 Venezuela Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.6 Peru Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.7 Puerto Rico Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.5.8 Ecuador Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.6.2 Kuwait Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.6.3 Oman Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.6.4 Qatar Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.7.2 South Africa Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.7.3 Egypt Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.7.4 Algeria Prophylactic Human Vaccine Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Prophylactic Human Vaccine Consumption (2017-2022)

      • 10.8.2 New Zealand Prophylactic Human Vaccine Consumption (2017-2022)

    11 Global Prophylactic Human Vaccine Competitive Analysis

    • 11.1 Merck

      • 11.1.1 Merck Company Details

      • 11.1.2 Merck Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Merck Prophylactic Human Vaccine Main Business and Markets Served

      • 11.1.4 Merck Prophylactic Human Vaccine Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 GSK

      • 11.2.1 GSK Company Details

      • 11.2.2 GSK Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 GSK Prophylactic Human Vaccine Main Business and Markets Served

      • 11.2.4 GSK Prophylactic Human Vaccine Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Merial

      • 11.3.1 Merial Company Details

      • 11.3.2 Merial Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Merial Prophylactic Human Vaccine Main Business and Markets Served

      • 11.3.4 Merial Prophylactic Human Vaccine Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Sanofi

      • 11.4.1 Sanofi Company Details

      • 11.4.2 Sanofi Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Sanofi Prophylactic Human Vaccine Main Business and Markets Served

      • 11.4.4 Sanofi Prophylactic Human Vaccine Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 McKesson Medical

      • 11.5.1 McKesson Medical Company Details

      • 11.5.2 McKesson Medical Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 McKesson Medical Prophylactic Human Vaccine Main Business and Markets Served

      • 11.5.4 McKesson Medical Prophylactic Human Vaccine Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Biovac

      • 11.6.1 Biovac Company Details

      • 11.6.2 Biovac Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Biovac Prophylactic Human Vaccine Main Business and Markets Served

      • 11.6.4 Biovac Prophylactic Human Vaccine Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Zoetis

      • 11.7.1 Zoetis Company Details

      • 11.7.2 Zoetis Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Zoetis Prophylactic Human Vaccine Main Business and Markets Served

      • 11.7.4 Zoetis Prophylactic Human Vaccine Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    12 Global Prophylactic Human Vaccine Market Outlook by Types and Applications to 2028

    • 12.1 Global Prophylactic Human Vaccine Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Attenuated Vaccine Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Prophylactic Human Vaccine Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Scientific Research Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Prophylactic Human Vaccine Market Analysis and Outlook to 2028

    • 13.1 Global Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.2.2 Canada Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.2 UK Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.3 Spain Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.5 France Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.6 Italy Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.8 Finland Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.9 Norway Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.11 Poland Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.12 Russia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.2 Japan Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.3 India Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.3 Chile Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.6 Peru Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.6.3 Oman Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Prophylactic Human Vaccine Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Prophylactic Human Vaccine Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Prophylactic Human Vaccine

    • Figure of Prophylactic Human Vaccine Picture

    • Table Global Prophylactic Human Vaccine Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Prophylactic Human Vaccine Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Inactivated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Global Attenuated Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Scientific Research Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Table North America Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure United States Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Canada Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Mexico Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table Europe Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure Germany Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure UK Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Spain Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Belgium Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure France Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Italy Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Denmark Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Finland Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Norway Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Sweden Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Poland Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Russia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Turkey Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table APAC Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure China Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Japan Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure India Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Korea Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Thailand Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Singapore Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Philippines Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table South America Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure Brazil Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Colombia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Chile Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Argentina Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Peru Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table GCC Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure Bahrain Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Oman Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Qatar Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table Africa Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure Nigeria Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure South Africa Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Egypt Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure Algeria Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table Oceania Prophylactic Human Vaccine Consumption by Country (2017-2022)

    • Figure Australia Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Prophylactic Human Vaccine Consumption and Growth Rate (2017-2022)

    • Table Merck Company Details

    • Table Merck Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merck Prophylactic Human Vaccine Main Business and Markets Served

    • Table Merck Prophylactic Human Vaccine Product Portfolio

    • Table GSK Company Details

    • Table GSK Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table GSK Prophylactic Human Vaccine Main Business and Markets Served

    • Table GSK Prophylactic Human Vaccine Product Portfolio

    • Table Merial Company Details

    • Table Merial Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Merial Prophylactic Human Vaccine Main Business and Markets Served

    • Table Merial Prophylactic Human Vaccine Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Prophylactic Human Vaccine Main Business and Markets Served

    • Table Sanofi Prophylactic Human Vaccine Product Portfolio

    • Table McKesson Medical Company Details

    • Table McKesson Medical Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table McKesson Medical Prophylactic Human Vaccine Main Business and Markets Served

    • Table McKesson Medical Prophylactic Human Vaccine Product Portfolio

    • Table Biovac Company Details

    • Table Biovac Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Biovac Prophylactic Human Vaccine Main Business and Markets Served

    • Table Biovac Prophylactic Human Vaccine Product Portfolio

    • Table Zoetis Company Details

    • Table Zoetis Prophylactic Human Vaccine Sales, Price, Value and Gross Profit (2017-2022)

    • Table Zoetis Prophylactic Human Vaccine Main Business and Markets Served

    • Table Zoetis Prophylactic Human Vaccine Product Portfolio

    • Figure Global Inactivated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Attenuated Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Scientific Research Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Table North America Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure United States Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Germany Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure China Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Brazil Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Prophylactic Human Vaccine Consumption Forecast by Country (2022-2028)

    • Figure Australia Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Prophylactic Human Vaccine Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US